Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Still in a blackout

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Jan 15, 2024 6:24pm

192 Views

Post# 35827934

RE:RE:RE:Still in a blackout

That's a classic line from Canadfan's playbook.

When literally NOTHING is happening in the world of ONC, he and other delusional enthusiasts will always attribute the radio silence to a "black-out period," thus eliciting excitment from a small crowd of naive investors and earning praise from MC.

In the meantime, ONC announces that they will be making an annoucement about an announcement of an update to their plans for FIVE (Yes, FIVE!!) different phase three trials expected to begin in H2, 2032.

<< Previous

Bullboard Posts

Next >>

Enbridge finalizes acquisition of three growing gas utilities